WPD Pharmaceuticals Inc. (WPDPF)

0.0000 0.0000 (0.00%) At close: 12:34PM EDT

WPD Pharmaceuticals Inc.

750 West Pender Street
Suite 401
Vancouver, BC V6C 2T7
Canada
604 561 2687
https://www.wpdpharmaceuticals.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mariusz Olejniczak	Chief Executive Officer	46.34k	N/A	N/A
Ms. Katarzyna Suchoszek Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Ms. Beata Pajak Eng., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Marek Sipowicz M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

WPD Pharmaceuticals Inc., a biotechnology research and development company, engages in the research and development of medicinal products in the fields of oncology. The company develops WPD101 to treat brain cancers; WPD102 for the treatment of uveal melanoma; Berubicin to treat glioblastoma multiforme; and WP1066 for the treatment of glioblastoma and melanoma brain metastases. It also develops WP1220 for the treatment of cutaneous T-cell lymphoma; WPD103, a radiopharmaceutical based on the expression of tumor-specific receptors, such as IL-13RA2 and EphA2; and Annamycin to treat solid tumors metastasis, breast, ovarian, lung, and lower gastrointestinal tract cancers. WPD Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Corporate Governance

WPD Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.